Topical corticosteroids are commonly pre scribed for the treatment of a range of inflam matory skin conditions. Although the adverse systemic effects of oral corticosteroids are well described, the association of topical corti costeroid exposure with metabolic sequelae is less clear 1 . In their recent publication in Diabetes Care, Andersen et al. 2 examine the association between topical corticoste roid use and risk of incident type 2 diabetes mellitus (T2DM). Using routinely collected healthcare data from Denmark and the UK, the researchers performed two nested casecontrol studies including a total of 170,162 adults with newonset T2DM and the equiva lent number of matched control individuals with no T2DM. A prospective cohort study was also performed using Danish data from than corticosteroids dispensed >1 year prior in both case-control studies. However, an inconsistent relationship between shortterm versus longterm use of topical corticosteroids and T2DM risk was observed 2 .
Topical corticosteroids were prescribed on one or more occasions to 39.1% of the 2.6 million individuals in the Danish cohort during the followup period 1 . More than onethird of patients with incident T2DM enrolled in the case-control studies were also exposed to topical corticosteroids in the preced ing 4 years (38.2% in the UK and 34.2% in Denmark) 2 . Although the burden of topical corticosteroid use is not well estab lished in large populations, these figures sug gest more liberal use than previous reports. For example, in a prospective study of 1,066 elderly patients with T2DM in Edinburgh, only 1.4% had been exposed to topical cor ticosteroids in the preceding 3 months 3 . Interestingly, in the present study, only a modest proportion of individuals in the UK and Denmark were diagnosed with a chronic skin disease at baseline 2 . For example, 17% of the UK cohort were diagnosed with eczema and 5% with psoriasis, suggesting a consider able proportion of topical corticosteroids are prescribed to treat shortterm or mild skin disease, which responds quickly to treatment.
The data in the present study assume patient adherence with prescribed topical corticosteroids. However, adherence with topical treatment was shown to be poor compared with the oral route and to decline rapidly over weeks in a prospective study involving patients with moderate to severe hand dermatitis 4 . Suboptimal adherence with antidiabetic medications has also been observed among people with T2DM. Only 65% of individuals with newly diagnosed T2DM in Singapore achieved excellent adher ence (≥80%) with antidiabetic medications, whereas mean adherence to insulin was 70.6% in Tayside, Scotland 5, 6 . By regarding 39.1% of the cohort population as exposed to topical ).
Exposure to topical corticosteroids in the preceding 4 years was associated with incident T2DM in both the UK (adjusted OR 1.27, 95% CI 1.23-1.31) and in Denmark (adjusted OR 1.25, 95% CI 1.23-1.28)
2 . An absolute risk difference of 2.17 (2.15-2.19) cases of T2DM per 1,000 persons per year was observed in association with exposure to topical cortico steroids. A positive dose-response relationship between topical corticosteroid potency and risk of T2DM was evident in both Danish studies, with very potent preparations asso ciated with the greatest increase in risk of T2DM 2 . Topical corticosteroid exposure <1 year before the onset of T2DM was more strongly associated with T2DM incidence Exposure to topical corticosteroids in the preceding 4 years was associated with incident T2DM in both the UK … and in Denmark
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Topical glucocorticoids and risk of type 2 diabetes mellitus
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A positive association between topical corticosteroid use and risk of type 2 diabetes mellitus has been reported in a large European population-based study. However, the increase in risk is small and should not influence the prescribing of topical corticosteroids when clinically indicated.
corticoste roids, regardless of the duration of treatment and adherence, it seems likely that the burden of exposure has been overesti mated, potentially exaggerating the relation ship between topical corticosteroid use and risk of T2DM.
Although the authors have adjusted for some potential confounding factors including smoking status and nontopical corticoste roid use, the ethnicity of the pop ulation was crucially not accounted for. Additionally, the Danish analyses adjusted for antihypertensive drugs, lipidlowering drugs and socio economic status as a proxy for BMI. We acknow ledge the practical dif ficulties in handling missing data; however, we would sug gest that these parameters are not always a robust surrogate for obe sity. Furthermore, it has been shown that people with T2DM receiving recent pre scribed corticosteroids through all routes (with the exception of intravenous) have a worse inflammatory profile and increased obesity, factors that might directly influ ence the pathogenesis of T2DM 3 . As the authors acknowledge, bacterial and fungal skin infections are more common in people with T2DM and therefore the potential for subsequent diagnosis of T2DM and reverse causality is present. It has been estimated that 40% of diabetes mellitus in the population is undiagnosed; therefore, it is likely that a considerable proportion of the study popu lation had undiagnosed T2DM at the time of topical corticosteroid exposure 7 . Glucocorticoids impact glucose metabo lism through complex mechanisms. These include the promotion of hepatic gluconeo genesis and inhibition of insulin secretion from pancreatic βcells 8 . Furthermore, insu lin resistance is induced through effects on hepatic, muscle and adipose tissue insulin receptors. As discussed by Andersen et al., top ical corticosteroids have a molecular weight that allows penetration of the epidermis and systemic absorption 2 . Alongside hypergly caemia, this systemic absorption is responsi ble for the other metabolic sequelae reported in association with topical cortico steroids. For example, hypothalamic-pituitary-adrenal axis suppression and iatro genic Cushing syn drome are recognized consequences of top ical corticosteroids, parti cularly in patients receiving longterm and very potent courses of topical corticosteroids 9 . Addi tionally, case reports of ocular hypertension, glaucoma and juvenile osteoporosis have been described in the literature 9, 10 . These data should not change prescrib ing practice as the observed association is of a small magnitude and causality can not be inferred from observational data.
Additionally, the issue of potential confound ers, which have not been accounted for, and reverse causality draw into question the validity of these results. In terms of implica tions for practice, these results highlight that routine monitoring of glycaemia or screening for diabetes mellitus should not be advised in patients receiving topical corti costeroids. However, prescribers should be mindful of the potential risk in patients receiving very potent preparations. These data will also allow med ical professionals and patients to discuss the low risks of treatment in more certain terms, should the need arise. . The risk was attenuated but persisted when the analy sis was restricted to women who did not develop diabetes mellitus during followup after delivery as compared with the whole cohort (RR 1.56, 95% CI 1.04-2.32) and was especially apparent in the first decade postpartum (RR 2.31, 95% CI 1.57-3.39).
Canadian investigators have expanded the association between plasma glucose concen tration and cardiovascular outcomes into the nondiagnostic range. A 2009 retrospective populationbased cohort study reported that after a followup of 12.3 years, women with GDM had an adjusted hazard ratio (HR) for a composite outcome of cardiovascular disease of 1.66 (95% CI 1.30-2.13); whereas preg nant women without a GDM diagnosis who received an oral glucose tolerance test had an
C A R D I OVA S C U L A R D I S E A S E
Glucose screening in pregnancy to predict future cardiovascular risk
Rosa Corcoy
High post-challenge glucose plasma concentrations that are observed during pregnancy screening can help to identify women who are at an increased likelihood of later health issues, predominantly cardiovascular diseases. This finding offers a unique opportunity to improve the health of women, but further work is required to translate into clinical benefits.
